Summary of Study ST001929

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001218. The data can be accessed directly via it's Project DOI: 10.21228/M88H76 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001929
Study TitleMetabolomics profiles of premenopausal women are different based on O-desmethylangolensin metabotype (Part 2)
Study SummaryUrinary O-desmethylangolensin (ODMA) concentrations provide a functional gut microbiome marker of dietary isoflavone daidzein metabolism to ODMA. Individuals who do not have gut microbial environments that produce ODMA have less favorable cardiometabolic and cancer risk profiles. Urinary metabolomics profiles were evaluated in relation to ODMA metabotypes within and between individuals over time. Secondary analysis was conducted of data from the BEAN2 trial, which was a cross-over study of premenopausal women consuming six months on a high- and a low-soy diet, each separated by a 1-month washout period. In all of the 672 samples in the study, 66 of the 84 women had the same ODMA metabotype at seven or all eight time points. Two or four urine samples per woman were selected based on temporal metabotypes in order to compare within and across individuals. Metabolomics assays for primary metabolism and biogenic amines were conducted in 60 urine samples from 20 women.
Institute
George Mason University
Last NameFrankenfeld
First NameCara
Address4400 University Drive, Fairfax, VA 22030
Emailprof.frankenfeld@gmail.com
Phone2062652563
Submit Date2021-08-23
Raw Data AvailableYes
Analysis Type DetailGC-MS
Release Date2021-11-02
Release Version1
Cara Frankenfeld Cara Frankenfeld
https://dx.doi.org/10.21228/M88H76
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001218
Project DOI:doi: 10.21228/M88H76
Project Title:Metabolomics profiles of premenopausal women are different based on O-desmethylangolensin metabotype
Project Summary:Urinary O-desmethylangolensin (ODMA) concentrations provide a functional gut microbiome marker of dietary isoflavone daidzein metabolism to ODMA. Individuals who do not have gut microbial environments that produce ODMA have less favorable cardiometabolic and cancer risk profiles. Urinary metabolomics profiles were evaluated in relation to ODMA metabotypes within and between individuals over time. Secondary analysis was conducted of data from the BEAN2 trial, which was a cross-over study of premenopausal women consuming six months on a high- and a low-soy diet, each separated by a 1-month washout period. In all of the 672 samples in the study, 66 of the 84 women had the same ODMA metabotype at seven or all eight time points. Two or four urine samples per woman were selected based on temporal metabotypes in order to compare within and across individuals. Metabolomics assays for primary metabolism and biogenic amines were conducted in 60 urine samples from 20 women. Partial least-squares discriminant analysis was used to compare metabolomics profiles.
Institute:George Mason University
Last Name:Frankenfeld
First Name:Cara
Address:4400 University Drive, Fairfax, VA 22030
Email:prof.frankenfeld@gmail.com
Phone:(206) 265-2563
Funding Source:Soy Health Research Program

Subject:

Subject ID:SU002007
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Subject treatment
SA178493180731bJWsa26_1B105u3.1_001 NC1
SA178494180801bJWsa07_1B105u4.2_002 NC1
SA178495180731bJWsa16_2B126u2.2_003 NC1
SA178496180731bJWsa48_1B126u7.2_004 NC1
SA178497180731bJWsa43_1B134u1.2_005 C0
SA178498180731bJWsa39_1B134u2.2_006 C0
SA178499180731bJWsa20_2B134u4.2_007 C0
SA178500180731bJWsa05_2B134u5.2_008 C0
SA178501180731bJWsa14_2B169u1.2_009 C0
SA178502180731bJWsa41_1B169u4.2_010 C1
SA178503180801bJWsa08_1B169u5.2_011 C0
SA178504180731bJWsa19_2B169u6.2_012 C1
SA178505180801bJWsa13_1B185u2.2_013 NC1
SA178506180801bJWsa06_1B185u5.2_014 NC1
SA178507180731bJWsa47_1B199u6.2_015 NC1
SA178508180731bJWsa24_2B199u7.2_016 NC1
SA178509180801bJWsa12_1B234u1.2_017 NC1
SA178510180731bJWsa06_2B234u6.2_018 NC1
SA178511180731bJWsa25_1B248u1.2_019 NC0
SA178512180731bJWsa10_2B248u2.2_020 NC0
SA178513180731bJWsa31_1B311u2.2_021 C1
SA178514180731bJWsa21_2B311u5.2_022 C1
SA178515180801bJWsa09_1B311u6.2_023 C0
SA178516180731bJWsa37_1B311u8.2_024 C0
SA178517180801bJWsa04_1B312u3.2_025 C0
SA178518180731bJWsa27_1B312u4.2_026 C0
SA178519180801bJWsa10_1B312u5.2_027 C1
SA178520180801bJWsa11_1B312u6.2_028 C1
SA178521180731bJWsa34_1B328u2.2_029 C1
SA178522180731bJWsa35_1B328u3.2_030 C1
SA178523180731bJWsa50_1B328u5.2_031 C0
SA178524180731bJWsa22_2B328u8.2_032 C0
SA178525180731bJWsa07_2B334u2.2_033 C0
SA178526180731bJWsa18_2B334u5.2_034 C1
SA178527180801bJWsa03_1B334u7.2_035 C0
SA178528180731bJWsa44_1B334u8.2_036 C1
SA178529180731bJWsa36_2B393u1.2_037 C1
SA178530180731bJWsa12_2B393u2.2_038 C0
SA178531180731bJWsa46_1B393u3.2_039 C0
SA178532180731bJWsa03_2B393u8.2_040 C1
SA178533180801bJWsa05_1B407u2.2_041 C0
SA178534180731bJWsa11_2B407u3.2_042 C0
SA178535180731bJWsa49_1B407u5.2_043 C1
SA178536180731bJWsa28_1B407u6.2_044 C1
SA178537180731bJWsa30_1B431u3.2_045 NC1
SA178538180801bJWsa01_1B431u5.2_046 NC1
SA178539180731bJWsa42_1B434u1.2_047 C0
SA178540180731bJWsa32_1B434u5.2_048 C0
SA178541180731bJWsa09_2B434u6.2_049 C1
SA178542180731bJWsa40_1B434u7.2_050 C1
SA178543180731bJWsa38_1B455u2.2_051 C1
SA178544180731bJWsa23_2B455u5.2_052 C1
SA178545180731bJWsa08_2B455u6.2_053 C0
SA178546180731bJWsa04_2B455u7.2_054 C0
SA178547180731bJWsa33_1B483u2.2_055 NC1
SA178548180731bJWsa17_2B483u7.2_056 NC1
SA178549180731bJWsa45_1B524u6.2_057 NC1
SA178550180731bJWsa13_2B524u8.2_058 NC1
SA178551180801bJWsa02_1B532u1.2_059 NC1
SA178552180731bJWsa29_1B532u4.4_060 NC1
SA178553180731bJWsa15_2B532u5.2_061 NC1
Showing results 1 to 61 of 61

Collection:

Collection ID:CO002000
Collection Summary:Urine biospecimens were collected during cross-over trial among premenopausal women conducted from 2007-2010, and details about the study design and population are published elsewhere (Morimoto et al 2014; Maskarinec et al 2011; Maskarinec et al 2012). The BEAN2 trial was a cross-over study with six months on a high- and a low-soy diet, each separated by a 1-month washout period. The objective of the study was to evaluate soy intake and nipple aspirate fluid, a possible indicator of breast cancer risk. Eligibility criteria for the parent study included a normal mammogram, no oral contraceptives, not pregnant, no previous cancer diagnosis or breast surgery, regular menstrual periods, low soy intake, and the ability to produce nipple aspirate fluid. There were 84 women from the original trial who had eight stored urine samples over the cross-over intervention, from which 60 samples were selected for metabolomics analysis.
Sample Type:Urine

Treatment:

Treatment ID:TR002019
Treatment Summary:As part of the parent study, daidzein, equol, and ODMA concentrations were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS) as detailed elsewhere (Franke et al 2009). These previously measured concentrations were used to classify metabotypes. Each urine sample was identified as being ODMA producer/non-producer and equol producer/non-producer based on a cut-off of equol/ODMA:daidzein ratio of 0.018 (36). All samples, except two samples, which were excluded from selection, had daidzein concentrations >2 nmol/mg creatinine, indicating sufficient presence of the precursor metabolite for metabolite detection.

Sample Preparation:

Sampleprep ID:SP002013
Sampleprep Summary:Urine samples were stored at -80C.

Combined analysis:

Analysis ID AN003137
Analysis type MS
Chromatography type GC
Chromatography system Leco Pegasus IV GC
Column Restek Rtx-5Sil MS (30 x 0.25mm, 0.25um)
MS Type EI
MS instrument type GC-TOF
MS instrument name Leco Pegasus IV TOF
Ion Mode POSITIVE
Units Peak height

Chromatography:

Chromatography ID:CH002319
Chromatography Summary:Urine samples were analyzed by the National Institutes of Health (NIH) West Coast Metabolomics Center in the Fiehn laboratory, using established protocols and more detail on these protocols are available elsewhere (Fiehn et al 2008). To consider broad aspects of metabolism relevant to diet, primary metabolism and biogenic amines platforms were evaluated. In brief, primary metabolism metabolites were assayed using automated liner exchange-cold injection system, gas chromatography-time of flight mass spectrometry (ALEX-CIS GCTOF).
Instrument Name:Leco Pegasus IV GC
Column Name:Restek Rtx-5Sil MS (30 x 0.25mm, 0.25um)
Chromatography Type:GC

MS:

MS ID:MS002917
Analysis ID:AN003137
Instrument Name:Leco Pegasus IV TOF
Instrument Type:GC-TOF
MS Type:EI
MS Comments:fter hard ionization by electron ionization, one electron gets abstracted from the intact molecules which hence become positively charged. The standardized -70 eV ionization voltage is so high that molecules fragment into multiple product ions, which may also form rearrangements among each other. Fragments are then analyzed by time of flight mass spectrometry which is made here by the vendor Leco corporation not to obtain accurate mass information at high resolution but instead to obtain mass spectra at very high sensitivity and speed. Mass spectrometry parameters are used as follows: a Leco Pegasus IV mass spectrometer is used with unit mass resolution at 17 spectra s-1 from 80-500 Da at -70 eV ionization energy and 1800 V detector voltage with a 230°C transfer line and a 250°C ion source.
Ion Mode:POSITIVE
  logo